Saturday, September 30, 2023
Saturday, September 30, 2023

Contact us 561.316.3330

Audicus Applauds FDA Announcement To Move Closer To Making Hearing Care More Accessible To Millions Of Americans

Audicus, the first company to offer fully customizable hearing aids online, and a leading provider of hearing aids via telehealth, responded today to the FDA’s proposed rule to establish a new category of over-the-counter (OTC) hearing aids. The proposed rule will allow for certain classes of hearing aids to be sold directly to consumers without the need for a fitting from an Audiologist, increasing accessibility to hearing care for the 37.5 million American adults with some form of hearing loss.

“Audicus pioneered the movement in making high quality hearing care more accessible and affordable nearly a decade ago,” said Patrick Freuler, Founder and CEO of Audicus. “We welcome the FDA’s proposed rule to create a class of OTC hearing aids and see it as a milestone towards greater access. This decision could only allow us to further reach those in need of hearing solutions, and deliver life-changing devices to them at a fraction of the cost of traditional channels,” he continued.

Throughout the COVID-19 pandemic, Audicus has seen the increased need to provide quality telehealth services, as well as a positive shift in seniors’ attitudes towards technology. In a survey of 330 seniors, Audicus found that 16% have used telemedicine services since the start of the pandemic, as compared to 5% before. Furthermore, 25% of seniors report now making video calls, as compared to 15% before. With this FDA proposal, Audicus recognizes that ongoing support through technology will be even more important for OTC hearing aids.

“We have helped hundreds of thousands of seniors learn about their hearing through our proprietary online hearing assessment and educational programming,” said Freuler, “and we look forward to continuing to provide expert care and support to the millions of seniors who are in need of hearing care.”

SourceAudicus
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

OTHER NEWS

4SC Receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

Jason Loveridge, Ph.D., CEO of 4SC, commented: “Receiving orphan drug designation for resminostat provides us with a number of important benefits, most crucially 7 years’ market exclusivity in the US, a key foundation of our efforts to commercialise Kinselby.  We are currently preparing a marketing authorisation application for Kinselby in the EU, which remains on track for submission in Q1 2024.”

Abyrx Receives FDA Clearance for MONTAGE ® Settable Bone Putty for Use in Cardiothoracic Surgery

By expanding the range of FDA-cleared surgical applications for MONTAGE, this latest milestone positions Abyrx to build upon the more than 25,000 units of MONTAGE that have been used to date by surgeons in trauma, orthopedics, sports medicine, foot and ankle, and craniomaxillofacial procedures.

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

By using this website you agree to accept Medical Device News Magazine Privacy Policy